Skip to main content
Premium Trial:

Request an Annual Quote

Health Canada Approves Two BCR-ABL Tests

NEW YORK (GenomeWeb) — Asuragen and MolecularMD announced today that Canadian regulators have approved their BCR-ABL tests for use in chronic myeloid leukemia (CML) patients.

According to Austin, Texas-based Asuragen, Health Canada has approved its qPCR-based QuantideX BCR-ABL IS kit. The test is designed to detect and quantify major breakpoint BCR-ABL1 fusion transcripts and is used to monitor molecular response in CML patients, regardless of tyrosine kinase inhibitor (TKI) therapy or disease management approach. The kit received US Food and Drug Administration premarket clearance in 2016 and CE marking in 2015. 

Meanwhile, MolecularMD said Health Canada has approved its PCR-based MRDx BCR-ABL test as an aid to monitor TKI treatment in Philadelphia chromosome positive CML patients, as well as for patients chronically treated with Novartis' Tasigna (nilotinib) who are candidates for discontinuation and monitoring of treatment-free remission. Patients in remission no longer taking Tasigna would continue to be monitored with MRDx BCR-ABL  — which is also FDA authorized and CE marked — to identify loss of molecular responses, MolecularMD noted.

Earlier this year, Portland, Oregon-based MolecularMD licensed the exclusive US marketing rights to the MRDx BCR-ABL test to Genoptix.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.